Transcript of "Senology.org Newsletter - June 1, 2012"
Senology Newsletter Page 1 of 4 Senology.org - Newsletter International Senologic and Oncologic Scientific Community (ISOSC) "Connecting specialists worldwide" Editor-in-Chief: Gian Paolo Andreoletti, MD Subscribe Unsubscribe Contact Back Issues Connecting Specialists Worldwide SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US! Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates Literature Selection Narod SA et al.: "Oophorectomy after Menopause and the Risk of Breast Cancer in BRCA1 and BRCA2 Mutation Carriers", Cancer Epidemiol Biomarkers Prev. 2012 May 7. [Epub ahead of print] Liu Y et al.: "Bisphosphonate Use and the Risk of Breast Cancer: A Meta-Analysis of Published Literature", Clin Breast Cancer. 2012 May 22. [Epub ahead of print] Kluger N et al.: "Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients", Ann Oncol. 2012 May 9. [Epub ahead of print] Giordano SH et al.: "Decline in the Use of Anthracyclines for Breast Cancer", J Clin Oncol. 2012 May 21. [Epub ahead of print] Takei H et al.: "Sentinel lymph node biopsy after neoadjuvant chemotherapy predicts pathological axillary lymph node status in breast cancer patients with clinically positive axillary lymph nodes at presentation", Int J Clin Oncol. 2012 May 16. [Epub ahead of print] Retsky M et al.: "NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup", Breast Cancer Res Treat. 2012 May 24. [Epub ahead of print] Kagara N et al.: "Epigenetic Regulation of Cancer Stem Cell Genes in Triple-Negative Breast Cancer", Am J Pathol. 2012 May 21. [Epub ahead of print] Comment "Neoadjuvant therapy for breast cancer has no benefits in routine clinical practice", Franck Bonnetain,file://C:Documents and SettingsutenteDesktopNewsl_Jun2012.htm 01/06/2012
Senology Newsletter Page 2 of 4 Biostatistics and Epidemiology Unit, Centre Georges Francois Leclerc (CGFL), Dijon, France "Our study, with a median follow-up of 11 years, confirms that, for patients with primary operable non-metastatic breast cancer, neoadjuvant chemotherapy failed to improve overall survival. Then added value of neoadjuvant strategy for patients clinical benefit remains uncertain without demonstrating improvement regarding health related quality of life. Furthermore, we found no difference in the final mastectomy rate between the treatment groups. Of note, it is important to underline that these results are based on an historical cohort. Such bias is inherent to long-term endpoint studies. Never mind our results underline that clinicians should pay caution against the use of neoadjuvant chemotherapy in an unselected population. Then we suggest that the use of neoadjuvant therapy in clinical practice should be carefully discussed before implementation to take into accounts the benefits and risks for the patient. Quality of life could be the cornerstone of this discussion." (Comment on: Le Ray I et al.: "Neoadjuvant therapy for breast cancer has no benefits on overall survival or on the mastectomy rate in routine clinical practice. A population-based study with a median follow-up of 11years using propensity score matching", Eur J Cancer. 2012 Apr 16. [Epub ahead of print) Share your opinion on LinkedIn® Calendar of Events 14th Milan Breast Cancer Conference, June 20-22, 2012, Milan, Italy Benign Breast Diseases, Breast Cancer and Basic Science, June 27-30, 2012, Naoussa, Macedonia, Greece IBUS Update in Breast Imaging, 19 - 22 September 2012, Ferrara, Italy 17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13, 2012, Salvador, Bahia, Brazil Breast Cancer in Young Women Conference, 8-10 November 8-10, 2012, Dublin, Ireland IBUS - International Breast Ultrasound Course, 13 - 15 November 2012, Tel Aviv, Israel 8th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 15-17, 2012, Padova , Italy Literature Selection Bach PB et al.: "Benefits and Harms of CT Screening for Lung Cancer: A Systematic ReviewBenefits and Harms of CT Screening for Lung Cancer", JAMA. 2012 May 20 [Epub ahead of print] Moyer VA et al.: "Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement", Ann Intern Med. 2012 May 21. [Epub ahead of print] Burmeister BH et al.: "Adjuvant radiotherapy versus observation alone for patients at risk of lymph- node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial, Lancet Oncol. 2012 May 8. [Epub ahead of print] Smalley SR et al.: "Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection", J Clin Oncol. 2012 May 14. [Epub ahead of print] Holdenrieder S et al.: "Cytokeratin serum biomarkers in patients with colorectal cancer", Anticancer Res. 2012 May;32(5):1971-6 Schoen RE et al.: "Colorectal-Cancer Incidence and Mortality with Screening Flexible Sigmoidoscopy", N Engl J Med. 2012 May 21. [Epub ahead of print] Palumbo A et al.: "Continuous lenalidomide treatment for newly diagnosed multiple myeloma", N Engl J Med. 2012 May 10;366(19):1759-69 Attal M et al.: "Lenalidomide maintenance after stem-cell transplantation for multiple myeloma", N Engl J Med. 2012 May 10;366(19):1782-91 McCarthy PL et al.: "Lenalidomide after stem-cell transplantation for multiple myeloma", N Engl J Med. 2012 May 10;366(19):1770-81 Garderet L et al.: "Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation", J Clin Oncol. 2012 May 14. [Epub ahead of print] Fragments of Historyfile://C:Documents and SettingsutenteDesktopNewsl_Jun2012.htm 01/06/2012
Senology Newsletter Page 3 of 4 Wilhelm Conrad Röntgen (Remscheid, Germany, 1845 – 1923): "On a new kind of rays", Science 1896 Feb 14;3(59):227-31 Discussion ""Benefit from adjuvant postoperative radiochemotherapy for curatively resected gastric cancer with primaries T3 or greater and/or positive nodes" - Share your opinion on LinkedIn® Literature Selection Antoine C et al.: "Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium", Maturitas. 2012 May 22. [Epub ahead of print] Nelson HD et al.: “Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendations”, Ann Intern Med 2012 May 28 [Epub ahead of print] Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation. TalkAboutHealth Q&A of the month "When would you recommend the TDAP (thoracodorsal artery perforator) flap breast reconstruction and are there any advantages of this procedure?" "There are several ways to borrow living tissue from the patient’s own body to replace the breast after mastectomy. Tissue is most commonly taken from the abdomen (TRAM, DIEP, SIEA) because there is commonly enough tissue there to make one or two breasts. Tissue can also be used from the buttocks, hips thighs and trunk. When tissue is taken from the trunk or side next to the breast we call it a lateral thoracic flap. The TDAP is one example. TDAP stands for Thoracodorsal Artery Perforator Flap. This is a local flap, meaning that it comes from near the area of the defect (breast). The skin and fat is harvested in one elliptical piece that is still connected to a tiny blood vessel that supplies it. This tissue is then moved over into the defect to either create a new breast or to correct a lumpectomy defect. TDAPs (and other lateral thoracic flaps) are used when there is enough volume of extra tissue at the donor area (the lateral thorax) to correct the defect caused by breast cancer surgery. Usually there is not enough extra tissue there to make a whole breast, so these procedures are most commonly used for partial breast reconstruction. The advantages of the lateral thoracic flaps are:1. Short hospital stay (24 hours). 2. Low failure rate 3. Favorable scar within the bra line. 4. Gets rid of unwanted extra tissue under the arm. " (Answer by Joshua Levine , The New York Center for the Advancement of Breast Reconstruction, New York, NY, USA) Stay informed.... Recent Advances in Clinical Medicine Becattini C et al.: "Aspirin for preventing the recurrence of venous thromboembolism ", N Engl J Med. 2012 May 24;366(21):1959-67file://C:Documents and SettingsutenteDesktopNewsl_Jun2012.htm 01/06/2012
Senology Newsletter Page 4 of 4 Unsubscribe www.senology.orgfile://C:Documents and SettingsutenteDesktopNewsl_Jun2012.htm 01/06/2012